The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.
The San Antonio-based firm also intends to file a 510(k) for clearance of the assay.
The clearance covers a respiratory viral test for both RSV and hMPV.
Quidel said that Diagnostic Hybrids' fluorescent in vitro diagnostic assays would complement Quidel's point-of-care diagnostics for infectious disease and reproductive health.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.